Amazon’s ( AMZN) free cash flow is likely to turn negative due to aggressive AI capital expenditures, while Google’s parent ...

Rotation from growth to value is underway, with value and dividend portfolios strongly outperforming S&P 500 and Nasdaq into ...

Drug test cups remain a frontline tool for employers, clinics, and occupational health providers who need fast, reliable urine screening ...

Ross Gerber prominent Wall Street investor is calling on Tesla to sell its electric vehicle business to rival Rivian, saying ...

Shannon Saccocia, CIO of wealth at Neuberger Berman, examines the sharp and broad sell-off in technology stocks as a major ...

Software (IGV) stocks have been experiencing an artificial intelligence (AI)–fueled sell-off, but many investors say the ...

MENLO PARK, Calif., Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial ...

MedGenome has announced the launch of MetaSeq, an advanced blood test designed to support faster and more comprehensive detection of bloodstream infections (BSI). MetaSeq uses metagenomic ...

Companies are realizing they can no longer simply promote themselves to potential customers. They have to win over the robots ...

Median's eyonis LCS is software is reimbursable under Medicare at a rate between $601 to $700.

Selloff grips legal tech and software names with investors reassessing software, private credit, and AI‑exposed holdings across public and private markets.

As of Thursday, February 19, Rapid Micro Biosystems, Inc.’s RPID share price has dipped by 6.00%, which has investors questioning if this is right time to buy.